We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A Q-TWiST analysis comparing panitumumab plus best supportive care (BSC) with BSC alone in patients with wild-type KRAS metastatic colorectal cancer.
- Authors
Wang, J; Zhao, Z; Barber, B; Sherrill, B; Peeters, M; Wiezorek, J
- Abstract
Panitumumab+best supportive care (BSC) significantly improved progression-free survival (PFS) vs BSC alone in patients with chemo-refractory wild-type KRAS metastatic colorectal cancer (mCRC). We applied the quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) analysis to provide an integrated measure of clinical benefit, with the objective of comparing quality-adjusted survival between the two arms. As the trial design allowed patients on BSC alone to receive panitumumab after disease progression, which confounded overall survival (OS), the focus of this analysis was on PFS.
- Publication
British journal of cancer, 2011, Vol 104, Issue 12, p1848
- ISSN
1532-1827
- Publication type
Journal Article
- DOI
10.1038/bjc.2011.179